Challenges and opportunities in New Zealand’s pharmaceutical sceneKevin Sheehy – Chief Executive, Medicines New Zealand

Dalton Kelly – Chief Executive, New Zealand Cancer Society

Assoc. Prof. Ken Whyte – University of Auckland Medical School

Medicines Access: Looking aheadKevin Sheehy General ManagerMedicines New Zealand

Opportunities for better health of patients are a challenge for funders

Clinical ResearchIt’s about improving healthcare

How do we sustain this improvement in healthcare?

Opportunities

Personalised medicine

Integrated decision making a complex problem

Medicine pipeline developments

Challenging demographics

Ageing population – degenerative illness

Later retirement

Funding challenges

Medicines Access: Looking ahead

“Genetics plays an important role in most diseases: cancer, obesity, diabetes, cardiovascular, neurologic and psychiatric diseases. All of medicine.” - Professor of Genetics at Harvard Medical School and first Scientific Director of the Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Dr. Raju Kucherlapati

Throat swabs or genetic tests Each have the ability to better target treatment Require integrated decision making (discussion between the budget silos)

Many new treatments are expensive to develop

but

can improve cost effectiveness by treating those who respond best

Personalised medicine

Contributing to New Zealand’s economic prosperity

Savings vs improved health

Include costs not currently considered

Back to work

Cost of disease to society

Compare to other health interventions

Ministry work commencing

Better understand value proposition

Integrated decision making

Over 20 new medicines per year registered by FDA Cancer Immunology Virology Metabolic diseases Neurology

Biologics

Increasing development complexity and costs

New indications

Medicine pipeline developments

OldModel

One chemistOne weekOne molecule

NewModel

One chemistOne computerOne robotOne week10,000 Molecules

Medicine pipeline developments cont

Age related illness

Non Communicable Diseases Heart, brain, metabolic, cancer

Ageing effect dominant reason for increasing cancer

Over 65s increasing by 4000 people per month

Retiring later?

R&D improving treatmentse.g. Biologicals for rheumatoid arthritis

Challenging demographics

Medicine = medical device = Surgery ?

But they are all fruit!Healthcare investments can and should be compared

Funding challenges

Making Named Patient Pharmaceutical Assessment (NPPA) work

Hospital medicines Greater transparency/engagement and responsiveness Measuring performance Understanding unmet needs

Current funding system challenges

Questions?